iwAL 2022

16–18 September 2022 | Nice, France

iwAL 2022

16–18 September 2022 | Nice, France

VJHemOnc is pleased to be the official media partner for the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 17 – 18 September, 2022.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in acute leukemias with the aim to optimize clinical care.

 

Session 1: Current challenges in clinical genomics

Koichi Takahashi
CHIP and clonal hematopoiesis in relation to AML
Koichi Takahashi The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
Claudia Lengerke
Fitness of leukemic stem cells
Claudia Lengerke University Hospital Tübingen , Tübingen, Germany
Courtney DiNardo
Current challenges in clinical genomics
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Paresh Vyas
Genomics and their clinical application for secondary AML
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Session 2: What is the standard of care in AML in 2022?

Eunice  Wang
Improving intensive chemotherapy approaches in frontline AML
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Andrew Wei
Maintenance therapy for whom?
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Charles Craddock
Which patients should have allogeneic transplants in 2022?
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Alessandro Rambaldi
Optimal transplant conditioning regimen in AML
Alessandro Rambaldi University of Milan, Milan, Italy
Christina Rautenberg
Optimizing therapy in secondary AML/RWE of CPX‐351
Christina Rautenberg University Hospital Essen, Essen, Germany
Stéphane  de Botton
Targeted approaches for IDH‐mutated AML ‐ venetoclax or IDHi?
Stéphane de Botton Gustave Roussy, Paris, France
Jessica Altman
Current approach for relapsed FLT3‐mutant AML
Jessica Altman Northwestern University, Chicago, IL, United States

Session 3: Novel treatment strategies in ALL

Daniel DeAngelo
Innovation in the treatment of ALL
Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States
Nicholas Short
Ponatinib combination strategies
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Nicolas Boissel
Progress in treatment of AYA ALL
Nicolas Boissel Saint-Louis Hospital, Paris, France
Robin Foà
Open questions in Ph+ ALL
Robin Foà Sapienza University of Rome, Italy
Rob  Pieters
Updates in asparaginase treatment strategies
Rob Pieters Princess Máxima Center, Utrecht, Netherlands

Session 4: New frontiers in MRD
Part 1 – ALL clinical practice

 

Nicola  Gökbuget
MRD in adult Ph‐/BCR‐ABL‐negative ALL: how best to eradicate?
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany

Session 4: New frontiers in MRD
Part 2 – AML clinical practice

 

Catherine Smith
Single‐cell sequencing and clinical applicability in detection and therapy of AML
Catherine Smith University of California, San Francisco, San Francisco, CA, United States
Farhad  Ravandi
Value of MRD assessment in non‐intensive regimens in AML
Farhad Ravandi MD Anderson Cancer Center, Houston, TX, United States
Andrew Wei
Novel approaches for integrating MRD into clinical trials
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Session 5: Special session on regulatory endpoints in AML

Kelly Norsworthy
The FDA’s perspective on regulatory endpoints in AML
Kelly Norsworthy Johns Hopkins Medicine, Baltimore, MD, United States
Naval Daver
A clinician’s perspective on endpoints and drug development in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 6: BPDCN & CMML

Naveen  Pemmaraju
Updates in diagnosis, pathogenesis and future directions in BPDCN
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Mrinal Patnaik
Updates in CMML diagnosis and treatment, future targets
Mrinal Patnaik Rochester, MN, United States

Session 7: ELN 2022 classifications

Andrew Wei
ELN 2022 classifications
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Session 8: Novel targets, combinations and treatments in AML
Part 1 – What is the next AML blockbuster?

Richard  Stone
Challenges in the treatment of high‐risk AML
Richard Stone Dana-Farber Cancer Institute, Boston, MA, United States
Naval Daver
Doublet and triplet combinations in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Roland Walter
Emerging novel antibody‐drug conjugates
Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Thomas  Cluzeau
TP53 treatment strategies in AML
Thomas Cluzeau Central University Hospital of Nice, Afghanistan
Eytan  Stein
Menin inhibitors in AML
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
David Sallman
Anti‐CD47
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Session 8: Novel targets, combinations and treatments in AML
Part 2 – What do we know about drug resistance?

Paresh Vyas
Understanding and overcoming resistance to IDHi
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Marina Konopleva
Targeting resistance to venetoclax‐based therapies
Marina Konopleva University of Texas MD Anderson Cancer Center, Houston, TX, United States
Alexander  Perl
Resistance to FLT3 inhibitors
Alexander Perl University of Pennsylvania, Philadelphia, PA, United States
Carsten Müller‐Tidow
Epigenetic therapies and Epitranscriptomics
Carsten Müller‐Tidow Heidelberg University Hospital, Heidelberg, Germany

Session 9: T‐cell engagement
Part 1 – roadmap on how to treat relapsed ALL

Nicola  Gökbuget
Use of monoclonal antibodies in the CAR T‐cell era
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Elias  Jabbour
Integration of immunotherapies into frontline ALL management
Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 9: T‐cell engagement
Part 2 – CAR-T in ALL

Bijal Shah
Predicting response to CAR‐T
Bijal Shah Lee Moffitt Cancer Center & Research Institute, Lee Moffitt Cancer Center & Research Institute, FL, United States
Sara Ghorashian
Tisagenlecleucel in B‐ALL
Sara Ghorashian Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Nicolas Boissel
ZUMA‐3 and brexucabtagene autoleucel indication for adult ALL
Nicolas Boissel Saint-Louis Hospital, Paris, France

Session 10: Immunotherapeutics in AML

Marion Subklewe
Pitfalls and future strategies for immunotherapies in AML
Marion Subklewe LMU Hospital Munich, Munich, Germany
Fang Liu
CLL1‐CD33 cCAR‐T
Fang Liu Chengdu Military General Hospital, Sichuan, China
Michael  Hudecek
Novel targets for CAR‐T in AML
Michael Hudecek University of Würzburg, Würzburg, Germany
Amer Zeidan
Immune checkpoint inhibitors in AML
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Naval Daver
Emerging NK cell‐based therapies in AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Saar  Gill
Which CAR T‐cell strategy in AML has the most promise?
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States

            iwAL 2022 was supported by:


 

For the latest updates in AML & ALL, click below to explore our dedicated channels

 

 

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter